// App-Quantinova.ai

DOP018 : Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

Researchers

Presenter

  • S. Travis

Principal Investigators

  • B. Feagan

  • L. Peyrin-Biroulet

  • R. Panaccione

  • S. Danese

  • A. Lazar

  • A. Robinson

  • R. Thakkar

  • B. Pappalardo

  • J. Petersson

  • M. Bereswill

  • N. Chen

  • M. Skup

Medical Centers

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Robarts Reserach Institute, London, ON, Canada

  • University Hospital of Lille, Lille, France

  • Istituto Clinico Humanitas, Milan, Italy

  • AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany

  • AbbVie Inc., North Chicago, Illinois, United States

Locations

  • United Kingdom

  • Canada

  • France

  • Italy

  • Germany

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Ophthalmology (OP)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved